Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850454 | 0.77 | ALDH1A1 (0.38) | ALDH1A1ALOX15KMT2AMEN1HTT | |
| SCHEMBL10697965 | 0.75 | HTT (0.38) | ALDH1A1ALOX15KMT2AMEN1HTT | |
| SCHEMBL10696369 | 0.74 | MEN1 (0.41) | ALDH1A1ALOX15KMT2AMEN1HTT | |
| SCHEMBL5858419 | 0.74 | MEN1 (0.41) | ALDH1A1ALOX15KMT2AMEN1HTT | |
| SCHEMBL28167241 | 0.74 | ALDH1A1 (0.33) | ALDH1A1ALOX15KMT2AMEN1HTT | |
| SCHEMBL3199580 | 0.73 | KMT2A (0.41) | ALDH1A1KMT2AHTTTSHRLMNA | |
| SCHEMBL10696689 | 0.72 | MEN1 (0.35) | ALDH1A1ALOX15KMT2AMEN1HTT | |
| SCHEMBL3217854 | 0.70 | KMT2A (0.47) | ALDH1A1KMT2AMEN1HTTTSHR | |
| SCHEMBL18825603 | 0.69 | SRC (0.37) | ALDH1A1ALOX15KMT2AMEN1HTT | |
| SCHEMBL1335024 | 0.67 | KMT2A (0.38) | ALDH1A1ALOX15KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605144-B2 | Enzyme catalyzed therapeutic compounds | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-20 | — | — | US | disclosed |
| EP-1200455-B1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | CELMED ONCOLOGY USA INC (CA) | 2009-04-22 | — | — | EP | disclosed |
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | CELMED ONCOLOGY (USA), INC. | 2009-03-12 | — | — | US | disclosed |
| US-7462605-B2 | Phosphoramidate compounds and methods of use | CELMED ONCOLOGY (USA), INC. (CA) | 2008-12-09 | — | — | US | disclosed |
| US-20070213307-A1 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | PARKER HUGHES INSTITUTE (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060293285-A1 | Aryl Phosphate Derivatives of d4T | PARKER HUGHES INSTITUTE (US) | 2006-12-28 | — | — | US | disclosed |
| US-7138388-B2 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. (CA) | 2006-11-21 | — | — | US | disclosed |
| EP-1359921-A4 | METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS | NEWBIOTICS INC (US) | 2006-09-06 | — | — | EP | disclosed |
| US-7071176-B2 | Aryl phosphate derivatives of AZT having anti-HIV activity | PARKER HUGHES INSTITUTE (US) | 2006-07-04 | — | — | US | disclosed |
| US-6528495-B1 | Para-bromo substitution on the aryl group shows markedly increased potency without undesirable levels of cytotoxic activity; inhibitors of HIV reverse transcriptase; phosphorus of the aryl phosphate is substituted with an amino acid | PARKER HUGHES INSTITUTE | 2003-03-04 | — | — | US | disclosed |
| US-20020151519-A1 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. (CA) | 2002-10-17 | — | — | US | disclosed |
| US-20020147175-A1 | Synergistic ECTA compositions | NEWBIOTICS, INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002056832-A2 | METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS | NEWBIOTICS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002039952-A2 | SYNERGISTIC ECTA COMPOSITIONS | NEWBIOTICS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002038576-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T | PARKER HUGHES INSTITUTE (US) | 2002-05-16 | — | — | WO | disclosed |
| EP-1200455-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | Newbiotics Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6350736-B1 | phenyl methoxyalaninyl phosphate derivatives of 2',3'-didehydro-2',3'-dideoxythymidine with an electron-withdrawing moiety, such as p-bromo, for enhanced hydrolysis, have increased potency without high cytotoxic activity; inhibitors of HIV reverse transcriptase; thymidine-kinase (TK)-deficient cells | PARKER HUGHES INSTITUTE | 2002-02-26 | — | — | US | disclosed |
| WO-2001007454-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| US-6030957-A | INHIBITING HIV(HUMAN IMMUNODEFICIENCY VIRUS) REVERSE TRANSCIPTASE IN CELLS INFECTED WITH HIV BY ADMINISTERING TO INFECTED CELLS ARYLPHOSPHATE DERIVATIVE OF 2',3'-DIDEHYDRO-2',3'-DIDEOXYTHYMIDINE | WAYNE HUGHES INSTITUTE (US) | 2000-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | MTAP, TYMP, INPP5D | ALDH1A1 3586/4885ALOX15 1708/4885KMT2A 2126/4885 |
| US-20020147175-A1 | Synergistic ECTA compositions | ENTPD1, ENTPD2, ENPP1 | ALDH1A1 2150/4885ALOX15 3387/4885KMT2A 3785/4885 |
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | TYMP, PNP, APRT | ALDH1A1 1280/4885ALOX15 4189/4885KMT2A 1342/4885 |
| US-20020151519-A1 | Methods to treat autoimmune and inflammatory conditions | SSB, ENPP2, TPMT | ALDH1A1 627/4885ALOX15 107/4885KMT2A 2621/4885 |
| US-20070213307-A1 | Methods to treat autoimmune and inflammatory conditions | SSB, ENPP2, TPMT | ALDH1A1 627/4885ALOX15 107/4885KMT2A 2621/4885 |
| US-20060293285-A1 | Aryl Phosphate Derivatives of d4T | PNP, TYMP, APRT | ALDH1A1 1008/4885ALOX15 4451/4885KMT2A 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.